Approach to the treatment of chronic heart failure in children
DOI:
https://doi.org/10.13112/pc.1079Keywords:
HEART FAILURE; CHILD; THERAPEUTICSAbstract
Heart failure in children is an important cause of morbidity and mortality in children. In the pediatric population, diverse causes lead to the development of heart failure. The most common causes are congenital heart defects, cardiomyopathies (hereditary or acquired), infectious, metabolic, and genetic disorders. Due to this etiological heterogeneity, the approach to a child with heart failure must be individualized. If possible, it is necessary to treat the underlying disease. In the adult population, well-developed algorithms are used both in the diagnosis and the treatment of heart failure. Research into new drugs in adulthood is constant, while in childhood, primarily due to the heterogeneity of the population and the relatively small number of subjects, it is more challenging. Therefore, we must continue to carefully monitor research on the adult population and hope that further research in children will lead to the use of newer drugs.
References
1. Rossano JW, Shaddy RE. Heart failure in children: etiology and treatment. J Pediatr. 2014;165(2):228-33.
2. Hsu DT, Pearson GD. Heart failure in children: part I: history, etiology, and pathophysiology. Circ Heart Fail. 2009;2(1):63-7.
3. Kaski JP, Limongelli G. Cardiomyopathy in children: importance of aetiology in prognosis. Lancet. 2014;383(9916):781-2.
4. Agrawal A, Janjua D, Zeyada AA, Elsheikh AT. Heart failure in children and adolescents: an update on diagnostic approaches and management. Pediatr Cardiol. 2021;42(3):417-32. doi:10.1007/s00246-021-02603-2.
5. Raissadati A, Haukka J, Patila T, Nieminen H, Jokinen E. Chronic disease burden after congenital heart surgery: a 47-year population-based study with 99% follow-up. J Am Heart Assoc. 2020;9(3):e01534. doi:10.1161/JAHA.119.015354.
6. Garcia AM, Beatty JT, Nakano SJ. Heart failure in single right ventricle congenital heart disease: physiological and molecular considerations. Am J Physiol Heart Circ Physiol. 2020;318(5):H947-H965. doi:10.1152/ajpheart.00518.2019.
7. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the medical management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.00000000001063.
8. Ahmed H, VanderPluym C. Medical management of pediatric heart failure. Curr Opin Cardiol. 2022;37(5):567-75. doi:10.1097/HCO.0000000000001076.
9. Ross RD. The Ross classification for heart failure in children after 25 years: a review and an age-stratified revision. Pediatr Cardiol. 2012;33(8):1295-300. doi:10.1007/s00246-012-0306-8.
10. Castaldi B, Cuppini E, Fumanelli J, et al. Chronic heart failure in children: state of the art and new perspectives. Int J Cardiol. 2023;371:50-8. doi:10.1016/j.ijcard.2022.11.030.
11. Amdani S, Conway J, George K, et al. Evaluation and management of chronic heart failure in children and adolescents with congenital heart disease: a scientific statement from the American Heart Association. Circulation. 2022;145(12):e646-e668. doi:10.1161/CIR.0000000000001052.
12. Satou GM, Lacro RV, Chung T, Gauvreau K, Jenkins KJ. Heart size on chest X-ray as a predictor of cardiac enlargement by echocardiography in children. Pediatr Cardiol. 2001;22(3):218-22.
13. Goldberg SJ, Valdes-Cruz LM, Sahn DJ, Allen HD. Two-dimensional echocardiographic evaluation of dilated cardiomyopathy in children. Am J Cardiol. 1983;52(10):1244-8.
14. Masarone D, Valente F, Rubino M, et al. Pediatric heart failure: a practical guide to diagnosis and management. Pediatr Neonatol. 2017;58(4):303-12.
15. Eindhoven JA, van den Bosch AE, Jansen PR, Boersma E, Roos-Hesselink JW. The usefulness of brain natriuretic peptide in complex congenital heart disease: a systematic review. J Am Coll Cardiol. 2012;60(22):2140-9. doi:10.1016/j.jacc.2012.02.092.
16. Koch A, Zink S, Singer H. B-type natriuretic peptide in paediatric patients with congenital heart disease. Eur Heart J. 2006;27(7):861-6. doi:10.1093/eurheartj/ehi773.
17. Januzzi JL Jr, Camacho A, Harrington RA. NT-proBNP as a biomarker in pediatric heart failure. J Am Coll Cardiol. 2020;76(11):1335-49. doi:10.1016/j.jacc.2020.06.082.
18. Avitabile CM, Leonard MB, Brodsky JL, et al. Usefulness of insulin-like growth factor 1 as a marker of heart failure in children and young adults after the Fontan palliation procedure. Am J Cardiol. 2015;115(6):816-20. doi:10.1016/j.amjcard.2014.12.041.
19. Alshawabkeh L, Rajpal S, Landzberg MJ, et al. Relationship of red cell distribution width to adverse outcomes in adults with congenital heart disease (from the Boston Adult Congenital Heart Biobank). Am J Cardiol. 2018;122(9):1557-64. doi:10.1016/j.amjcard.2018.07.019.
20. Opotowsky AR, Valente AM, Alshawabkeh L, et al. Prospective cohort study of C-reactive protein as a predictor of clinical events in adults with congenital heart disease: results of the Boston Adult Congenital Heart Disease Biobank. Eur Heart J. 2018;39(32):3253-61. doi:10.1093/eurheartj/ehy362.
21. Mitchell FM, Prasad SK, Greil GF, Drivas P, Vassiliou PS, Raphael CE. Cardiovascular magnetic resonance: diagnostic utility and specific considerations in the pediatric population. World J Clin Pediatr. 2016;5(1):1-15.
22. Feltes TF, Bacha E, Beekman RH, et al. Indications for cardiac catheterization and intervention in pediatric cardiac disease: a scientific statement from the American Heart Association. Circulation. 2011;123(22):2607-52. doi:10.1161/CIR.0b013e31821b1f10.
23. Brown DW, Tweddell JS, Eghtesady P. Surgical management of congenital heart defects. Ann Thorac Surg. 2021;111(4):1164-1178. doi:10.1016/j.athoracsur.2020.08.010.
24. Almond CS, Morales DL, Rossano JW. Mechanical support and transplantation in pediatric heart failure. J Thorac Cardiovasc Surg. 2023;165(6):1860-71. doi:10.1016/j.jtcvs.2022.06.010.
25. Hollander SA. Malnutrition in pediatric heart failure. American College of Cardiology. [Internet]. [cited 2023 Jun 16]. Available from: https://acc.org/latest-in-cardiology/articles/2019/02/04/06/39/malnutrition-in-pediatric-heart-failure
26. Meltzer JS, Moitra VK. The nutritional and metabolic support of heart failure in the intensive care unit. Curr Opin Clin Nutr Metab Care. 2008;11(2):140-6.
27. Barbiero SM, D’Azevedo Sica C, Schuh DS, Cesa CC, de Oliveira Petkowicz R, Pellanda LC. Overweight and obesity in children with congenital heart disease: combination of risks for the future? BMC Pediatr. 2014;14:271. doi:10.1186/1471-2431-14-271.
28. Puri K, Price JF, Spinner JA, et al. Iron deficiency is associated with adverse outcomes in pediatric heart failure. J Pediatr. 2020;216:58-66.e1. doi:10.1016/j.jpeds.2019.08.060.
29. Puri K, Spinner JA, Powers JM, et al. Poor efficacy of oral iron replacement therapy in pediatric patients with heart failure. Cardiol Young. 2022;32(8):1302-9. doi:10.1017/S1047951121004066.
30. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005;111(21):2837-49.
31. Kantor PF, Lougheed J, Dancea A, et al. Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines. Can J Cardiol. 2013;29(12):1535-52.
32. Price JF. Congestive heart failure in children. Pediatr Rev. 2019;40(2):60-70.
33. Allen HD, Flanigan KM, Thrush PT, et al. A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in Duchenne muscular dystrophy. PLoS Curr. 2013 Dec 12; Edition 1. doi:10.1371/currents.md.2cc69a1dae4be7dfe2bcb420024ea865.
34. Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(2):137-55. doi:10.1002/ejhf.1369.
35. Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017;377(20):1964-75. doi:10.1056/NEJMra1703100.
36. Amdani S, Marino BS, Rossano J, Lopez R, Schold JD, Tang WHW. Burden of pediatric heart failure in the United States. J Am Coll Cardiol. 2022;79(18):1917-28. doi:10.1016/j.jacc.2022.03.336.
37. Hussey AD, Weintraub RG. Drug treatment of heart failure in children: focus on recent recommendations from the ISHLT guidelines for the management of pediatric heart failure. Paediatr Drugs. 2016;18(2):89-99.
38. DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res. 2006;53(5):399-406.
39. Bonnet D, Berger F, Jokinen E, Kantor PF, Daubeney PE. Ivabradine in children with dilated cardiomyopathy and symptomatic chronic heart failure. J Am Coll Cardiol. 2017;70(10):1262-72.
40. Adorisio R, Calvieri C, Cantarutti N, et al. Heart rate reduction strategy using ivabradine in end-stage Duchenne cardiomyopathy. Int J Cardiol. 2019;280:99-103. doi:10.1016/j.ijcard.2019.01.052.
41. McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004.
42. Rossano JW, Shaddy RE. Novel pharmacological approaches in pediatric heart failure. J Heart Lung Transplant. 2022;41(2):185-95. doi:10.1016/j.healun.2021.10.005.
43. Shaddy R, Burch M, Kantor PF, et al. Sacubitril/valsartan in pediatric heart failure (PANORAMA-HF): a randomized, multicenter, double-blind trial. Circulation. 2024;150(22):Sep 25. doi:10.1161/CIRCULATIONAHA.123.066605.
44. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008.
45. Newland DM, Hong BJ, Albers EL, et al. Safety of dapagliflozin in children with heart failure. J Heart Lung Transplant. 2021;40(Suppl):S280.
46. Efficacy, safety, and pharmacokinetics of vericiguat in pediatric participants with heart failure due to left ventricular systolic dysfunction (MK-1242-036) [Internet]. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT05714085.
47. Teerlink JR, Diaz R, Felker GM, et al. Effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in GALACTIC-HF. J Am Coll Cardiol. 2021;78(1):97-108.
48. Termosesov S, Garipov R, Ililich I. ICD therapy in paediatric practice. Europace. 2011;13(Suppl 2):i28-29.
49. Cecchin F, Frangini PA, Brown D, et al. Cardiac resynchronization therapy (and multisite pacing) in pediatrics and congenital heart disease: five years’ experience in a single institution. J Cardiovasc Electrophysiol. 2009;20(1):58-65.
50. Janousek J, Gebauer RA, Abdul-Khaliq H, et al. Cardiac resynchronisation therapy in paediatric and congenital heart disease: differential effects in various anatomical and functional substrates. Heart. 2009;95(14):1165-71.
51. Clark JB, Pauliks LB, Myers JL, Undar A. Mechanical circulatory support for end-stage heart failure in repaired and palliated congenital heart disease. Curr Cardiol Rev. 2011;7(2):102-9.
52. Martens S, Tie H, Kehl HG, et al. Heart transplantation surgery in children and young adults with congenital heart disease. J Cardiothorac Surg. 2023;18:342. https://doi.org/10.1186/s13019-023-02461-5.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Neven Čače
This work is licensed under a Creative Commons Attribution 4.0 International License.
By publishing in Paediatria Croatica, authors retain the copyright to their work and grant others the right to use, reproduce, and share their research articles in accordance with the Creative Commons Attribution License (CC BY 4.0), which allows others to distribute and build upon the work as long as they credit the author for the original creation.
